Physician
Sharma Institute of Pain Medicine
Sharma Institute of Pain Medicine was paid $740K by Medicaid between Jan 2018 and Dec 2024, across 51 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 43% of everything it billed.
33Billing provider infoSHARMA INSTITUTE OF PAIN MEDICINE
OCALA, FL 34474
OCALA, FL 34474
33aNPI1134420672assigned 11/16/2010
33bProvider typePain Medicine (Physical Medicine & Rehabilitation) Physician
28Total paid$740K
24GClaims102,675
24DCodes billed51
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pain Medicine (Physical Medicine & Rehabilitation) Physician providers in Florida
Rank by total paid#1 of 44
Median peer was paid$3K
This provider vs. median215×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,100 | $6K | |
| 2019 | 17,762 | $74K | |
| 2020 | 21,573 | $148K | |
| 2021 | 17,795 | $200K | |
| 2022 | 10,729 | $65K | |
| 2023 | 12,005 | $130K | |
| 2024incomplete | 7,711 | $117K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 43% | 21,479 | 18,967 | $319K |
| 80346 | 15% | 3,185 | 2,952 | $114K | |
| 80356 | 7.4% | 3,185 | 2,953 | $55K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.7% | 3,278 | 2,907 | $50K |
| 80325 | 6.1% | 3,185 | 2,951 | $45K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.3% | 408 | 361 | $24K |
| 80368 | 3.0% | 1,508 | 1,423 | $22K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.8% | 2,494 | 2,380 | $21K |
| 80372 | 2.4% | 1,508 | 1,422 | $17K | |
| 80348 | 1.1% | 3,185 | 2,951 | $8K | |
| 80361 | 1.1% | 3,187 | 2,954 | $8K | |
| 80370 | 1.1% | 3,188 | 2,954 | $8K |
39 more codes
| 80353 | 1.0% | 3,187 | $8K | |
| 80305 | <1% | 1,104 | $5K | |
| 80323 | <1% | 1,578 | $4K | |
| 80366 | <1% | 628 | $4K | |
| 80332 | <1% | 629 | $4K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 4,459 | $3K |
| 80349 | <1% | 1,508 | $2K | |
| 83992 | <1% | 1,504 | $2K | |
| 80365 | <1% | 599 | $2K | |
| 80373 | <1% | 596 | $2K | |
| 80358 | <1% | 598 | $2K | |
| 80354 | <1% | 595 | $2K | |
| 80363 | <1% | 595 | $2K | |
| 80360 | <1% | 599 | $2K | |
| 64445 | <1% | 48 | $2K | |
| 80359 | <1% | 595 | $2K | |
| J3490 | Unclassified drugs | <1% | 157 | $2K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,485 | $498.85 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 176 | $432.81 |
| 20610 | <1% | 52 | $41.84 | |
| G8482 | Influenza immunization administered or previously received | 0% | 3,957 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 3,389 | $0.00 |
| 4004F | 0% | 1,604 | $0.00 | |
| G9899 | Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results documented and reviewed | 0% | 1,873 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 4,872 | $0.00 |
| 1090F | 0% | 866 | $0.00 | |
| 4040F | 0% | 1,367 | $0.00 | |
| 99490 | Ccm add 20min | 0% | 67 | $0.00 |
| G9708 | Women who had a bilateral mastectomy or who have a history of a bilateral mastectomy or for whom there is evidence of a right and a left unilateral mastectomy | 0% | 40 | $0.00 |
| 3288F | 0% | 79 | $0.00 | |
| 80355 | 0% | 20 | $0.00 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 2,283 | $0.00 |
| 1101F | 0% | 1,355 | $0.00 | |
| 1036F | 0% | 2,227 | $0.00 | |
| G9906 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | 0% | 1,548 | $0.00 |
| 3017F | 0% | 2,937 | $0.00 | |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 1,636 | $0.00 |
| 1006F | 0% | 2,016 | $0.00 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 57 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHARMA, ANUJ (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Anuj Sharma DDS LLC | Lawrence, MA | $1.96M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.